Axsome Therapeutics (AXSM) Common Equity (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Common Equity data on file, last reported at $54.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 2.6% year-over-year to $54.6 million; the trailing twelve-month figure through Mar 2026 stood at $54.6 million (up 2.6% YoY), and the FY2025 full-year result was $88.3 million, up 54.86% from the prior year.
• Common Equity slipped to $54.6 million in Q1 2026, from $88.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $278.8 million in Q2 2023 to a low of $14.7 million in Q1 2022.
• A 5-year average of $111.0 million and a median of $92.9 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 84.74% in 2022 and jumped 1734.36% in 2023, its largest moves.
• Tracing AXSM's Common Equity over 5 years: stood at $109.6 million in 2022, then surged by 74.32% to $191.0 million in 2023, then sank by 70.15% to $57.0 million in 2024, then surged by 54.86% to $88.3 million in 2025, then plunged by 38.18% to $54.6 million in 2026.
• Business Quant data shows AXSM's Common Equity at $54.6 million in Q1 2026, $88.3 million in Q4 2025, and $73.7 million in Q3 2025.